PDFE-2304 (Neopili)
PDFE-2304 (Neopili) is in Phase 2 for androgenetic alopecia, developed by PDFE Pharma Innovations.
A topical of undisclosed composition, tested against minoxidil in fifteen men at one site in India.
- Developed by
- PDFE Pharma Innovations
- Current phase
- Phase 2
- Mechanism
- Undisclosed
- Indications
- Androgenetic alopecia
- Also known as
- PDFE-2304, PDFE2304, Neopili, NEOPILI
- Last public activity
- June 2025
- Copy last reviewed
- September 2026
- Record confidence
- Low
Tests whether it works, at what dose, in a few hundred people.
The sponsor has not said how it is supposed to work.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
Why it matters
Recorded because it is registered as a Phase 2, not because much is known. The trial compares PDFE-2304 with 5% minoxidil in 15 men in Koppal, Karnataka, was due to complete in September 2025, and has not been updated since June 2025. The sponsor, a Dubai free-zone company, describes the product only as a topical for androgenetic alopecia and reports a mouse study, no more. Treat every figure from this programme as unverified until a result appears in the registry.
Development history
- Phase 2
First Phase 2 trial on record: NCT07011485 — A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.
PDFE Pharma Innovations FZCO · n=15 · May 2025
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia — ClinicalTrials.gov
- PDFE Pharma Innovations — Neopili — Company release
Related programmes
Other programmes in the register with the same approach.
Cite this page
Hair Pipeline, "PDFE-2304 (Neopili) — development record", hairpipeline.com/pipeline/pdfe-2304